These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 24627546)

  • 21. Deferasirox for the treatment of chronic iron overload in transfusional hemosiderosis.
    Shashaty G; Frankewich R; Chakraborti T; Choudary J; Al-Fayoumi S; Kacuba A; Castillo S; Robie-Suh K; Rieves D; Weiss K; Pazdur R
    Oncology (Williston Park); 2006 Dec; 20(14):1799-1806, 1811; discussion 1811-13, 1817. PubMed ID: 17263129
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparative efficacy and safety of deferoxamine, deferiprone and deferasirox on severe thalassemia: a meta-analysis of 16 randomized controlled trials.
    Xia S; Zhang W; Huang L; Jiang H
    PLoS One; 2013; 8(12):e82662. PubMed ID: 24376563
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and safety of deferasirox in β-thalassemia major patients in Iran: a prospective study from a single referral center in Iran.
    Alavi S; Ebadi M; Ghazizadeh F; Arzanian MT; Shamsian B; Abdollah Gorji F
    Pediatr Hematol Oncol; 2014 Feb; 31(1):76-86. PubMed ID: 24383712
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Deferasirox administration for the treatment of non-transfusional iron overload in patients with thalassaemia intermedia.
    Ladis V; Berdousi H; Gotsis E; Kattamis A
    Br J Haematol; 2010 Dec; 151(5):504-8. PubMed ID: 20950401
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and safety of a novel combination of two oral chelators deferasirox/deferiprone over deferoxamine/deferiprone in severely iron overloaded young beta thalassemia major patients.
    Elalfy MS; Adly AM; Wali Y; Tony S; Samir A; Elhenawy YI
    Eur J Haematol; 2015 Nov; 95(5):411-20. PubMed ID: 25600572
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Compliance and satisfaction with deferasirox (Exjade®) compared with deferoxamine in patients with transfusion-dependent beta-thalassemia.
    Haghpanah S; Zarei T; Zahedi Z; Karimi M
    Hematology; 2014 Jun; 19(4):187-91. PubMed ID: 24074344
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Lifetime cost-utility analyses of deferasirox in beta-thalassaemia patients with chronic iron overload: a UK perspective.
    Karnon J; Tolley K; Vieira J; Chandiwana D
    Clin Drug Investig; 2012 Dec; 32(12):805-15. PubMed ID: 23026844
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Longitudinal prospective comparison of pancreatic iron by magnetic resonance in thalassemia patients transfusion-dependent since early childhood treated with combination deferiprone-desferrioxamine vs deferiprone or deferasirox monotherapy.
    Ricchi P; Meloni A; Pistoia L; Gamberini MR; Cuccia L; Allò M; Putti MC; Spasiano A; Rosso R; Cecinati V; Righi R; Renne S; Peritore G; Vallone A; Positano V; Quaia E; Cademartiri F; Pepe A
    Blood Transfus; 2024 Jan; 22(1):75-85. PubMed ID: 37146300
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Deferasirox and children: From clinical trials to the real world.
    Origa R; Zappu A; Foschini ML; Leoni G; Morittu M; Moi P; Corpino M; Dessì C
    Am J Hematol; 2016 Jun; 91(6):E304-5. PubMed ID: 26950047
    [No Abstract]   [Full Text] [Related]  

  • 30. Effectiveness and Safety of Deferasirox in Thalassemia with Iron Overload: A Meta-Analysis.
    Dou H; Qin Y; Chen G; Zhao Y
    Acta Haematol; 2019; 141(1):32-42. PubMed ID: 30504715
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Iron-chelating therapy for transfusional iron overload.
    Brittenham GM
    N Engl J Med; 2011 Jan; 364(2):146-56. PubMed ID: 21226580
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Profile of deferasirox for the treatment of patients with non-transfusion-dependent thalassemia syndromes.
    Ricchi P; Marsella M
    Drug Des Devel Ther; 2015; 9():6475-82. PubMed ID: 26719673
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Five Years of Deferasirox Therapy for Cardiac Iron in β-Thalassemia Major.
    Vlachaki E; Agapidou A; Spanos G; Klonizakis P; Vetsiou E; Mavroudi M; Boura P
    Hemoglobin; 2015; 39(5):299-304. PubMed ID: 26177199
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A 5-year follow-up in deferasirox treatment: improvement of cardiac and hepatic iron overload and amelioration in cardiac function in thalassemia major patients.
    Cassinerio E; Roghi A; Orofino N; Pedrotti P; Zanaboni L; Poggiali E; Giuditta M; Consonni D; Cappellini MD
    Ann Hematol; 2015 Jun; 94(6):939-45. PubMed ID: 25563596
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Chelation therapy for iron overload.
    Barton JC
    Curr Gastroenterol Rep; 2007 Mar; 9(1):74-82. PubMed ID: 17335681
    [TBL] [Abstract][Full Text] [Related]  

  • 36. How I treat transfusional iron overload.
    Hoffbrand AV; Taher A; Cappellini MD
    Blood; 2012 Nov; 120(18):3657-69. PubMed ID: 22919029
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Deferasirox (Exjade) significantly improves cardiac T2* in heavily iron-overloaded patients with beta-thalassemia major.
    Pathare A; Taher A; Daar S
    Ann Hematol; 2010 Apr; 89(4):405-9. PubMed ID: 19798501
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A randomised comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease.
    Vichinsky E; Onyekwere O; Porter J; Swerdlow P; Eckman J; Lane P; Files B; Hassell K; Kelly P; Wilson F; Bernaudin F; Forni GL; Okpala I; Ressayre-Djaffer C; Alberti D; Holland J; Marks P; Fung E; Fischer R; Mueller BU; Coates T;
    Br J Haematol; 2007 Feb; 136(3):501-8. PubMed ID: 17233848
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Therapeutic efficacy of different iron chelators in Egyptian children with Beta Thalassemia with iron overload.
    Hagag AA; Hamam MA; Taha OA; Hazaa SM
    Infect Disord Drug Targets; 2015; 15(2):98-105. PubMed ID: 26205801
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Continued improvement in myocardial T2* over two years of deferasirox therapy in β-thalassemia major patients with cardiac iron overload.
    Pennell DJ; Porter JB; Cappellini MD; Chan LL; El-Beshlawy A; Aydinok Y; Ibrahim H; Li CK; Viprakasit V; Elalfy MS; Kattamis A; Smith G; Habr D; Domokos G; Roubert B; Taher A
    Haematologica; 2011 Jan; 96(1):48-54. PubMed ID: 21071497
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.